| Patient | Wilma Mankiller |
|---|---|
| Date of birth | 1991-11-18 |
| Identifiers | MRN HR-ML052-SYN; SSN (made up) 000-52-4183 |
| Document date | 2026-08-24 |
| Author | Rena Hawkfeather-Lindqvist, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic preventive visit; no new complaints. [S]
Ms. Mankiller, a 34-year-old woman with generalized myasthenia gravis, returns for her periodic preventive visit eleven weeks after robotic thymectomy. She completed the health risk assessment beforehand. Her eyelids no longer droop and double vision has not returned; she tires a little by late afternoon. She takes pyridostigmine 60 mg four times daily, prednisone (now 30 mg each morning and tapering), azathioprine 150 mg daily, trimethoprim-sulfamethoxazole three times a week, calcium and vitamin D. She sleeps less well on prednisone and has gained about 3 kg since the spring. She has had no breathlessness, swallowing trouble or infections. She is back at work most days and walks with a cane only on rough ground. She asks which vaccines and screening she needs while on these medicines. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit |
| Safety events | No falls, infections or emergency visits since the thymectomy |
| Medicines | Pyridostigmine 60 mg four times daily; prednisone 30 mg daily, tapering; azathioprine 150 mg daily; trimethoprim-sulfamethoxazole three times weekly; calcium carbonate and cholecalciferol |
| Active conditions | Generalized myasthenia gravis after thymectomy; autosomal dominant polycystic kidney disease with normal kidney function; recovery from major trauma |
| Functional status | Independent; cane on rough ground |
Health risk assessment. Completed by the patient before the visit and reviewed during the visit. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good and improving |
| Psychosocial | Close ties to her community and work; the year since the crash has been hard; she has people to turn to |
| Tobacco | Never |
| Alcohol and drugs | None (AUDIT-C 0) |
| Physical activity | Walks most evenings; leg exercises from physical therapy three times a week |
| Nutrition | Home-cooked meals; less salt for her kidneys; more hungry on prednisone; drinks about 2.5 liters of water a day |
| Sleep | Wakes early on prednisone; about six hours |
| Safety at home | Feels safe at home; no violence or threats (screen negative) |
| Driving and seat belts | Always wears a seat belt; drives in daylight |
| Reproductive health | Not planning pregnancy; reports a reliable method of contraception, not recorded here |
| Sun exposure | Works outdoors at times; hat and sunscreen advised on azathioprine |
| Pain | Occasional aching in the left leg after long days |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Weight up about 3 kg on prednisone; mild late-afternoon tiredness; no fever |
| Eyes | Negative | No drooping eyelids or double vision |
| Ears, nose, mouth, and throat | Negative | No trouble chewing or swallowing; voice normal |
| Cardiovascular | Negative | No chest pain, palpitations or swelling |
| Respiratory | Negative | No breathlessness lying flat; cough strong |
| Gastrointestinal | Negative | Loose stools on pyridostigmine at times; no abdominal pain |
| Genitourinary | Negative | No blood in the urine, flank pain or urinary infections |
| Musculoskeletal | Positive | Occasional left leg ache after long days; no new joint pain |
| Integumentary | Negative | Healed thymectomy port sites; no new skin lesions |
| Neurological | Negative | No weakness of the arms or neck; no numbness |
| Psychiatric | Negative | Mood steady; sleep shorter on prednisone; PHQ-9 score 3 |
| Endocrine | Negative | No excess thirst or urination |
12 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eating | One tablet three times daily | Oral route | 2026-03-09 to 2026-03-23 | completed | S |
| Pyridostigmine bromide 60 mg oral tablet, one tablet four times daily while awake, 30 to 45 minutes before meals | One tablet four times daily while awake | Oral route | 2026-03-23 to 2026-10-12 | completed | S |
| Prednisone 10 mg oral tablet, 10 mg each morning, rising by 10 mg each week to 40 mg each morning, then held at 40 mg | Once each morning; dose as directed | Oral route | 2026-03-23 to 2026-07-13 | completed | S |
| Prednisone 5 mg oral tablet, tapering from 40 mg each morning by 5 mg every two to three weeks | Once each morning; dose as directed | Oral route | 2026-07-13 | active | S |
| Azathioprine 50 mg oral tablet, one tablet daily for two weeks, then two tablets daily, then three tablets (150 mg, about 2.3 mg/kg) daily | Once daily; dose as directed | Oral route | 2026-05-04 | active | S |
| Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet daily with food | One tablet daily with food | Oral route | 2026-03-23 | active | S |
| Cholecalciferol (vitamin D3) 1000 units (0.025 mg) oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Sulfamethoxazole 800 mg / trimethoprim 160 mg oral tablet, one tablet three times a week, while prednisone is 20 mg or more with azathioprine | One tablet on Monday, Wednesday and Friday | Oral route | 2026-05-04 to 2026-10-05 | completed | S |
| Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg pain | One or two tablets up to three times daily as needed | Oral route | 2025-09-15 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-08-24 | Body height | 163 | cm | S |
| 2026-08-24 | Body weight | 64.2 | kg | S |
| 2026-08-24 | Body mass index (BMI) [Ratio] | 24.2 | kg/m2 | S |
| 2026-08-24 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-08-24 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-08-24 | Heart rate | 72 | /min | S |
| 2026-08-24 | Respiratory rate | 14 | /min | S |
| 2026-08-24 | Body temperature | 36.6 | Cel | S |
| 2026-08-24 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-08-24 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-08-24 | Total score [AUDIT-C] | 0 | {score} | S |
Vital signs recorded on 2026-08-24; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Well; weight 64.2 kg, BMI 24.2; blood pressure 120/76 |
| Eyes | No ptosis after one minute of upgaze; eye movements full |
| Neck | Neck flexion strength 5 of 5; no thyroid enlargement |
| Cardiovascular | Regular rhythm; no murmur; no edema |
| Respiratory | Clear; healed port sites on the right chest |
| Breasts | Clinical breast examination declined; not required at her age |
| Abdomen | Soft; both kidneys palpable, non-tender |
| Musculoskeletal | Healed surgical scars on both legs; walks steadily without the cane in the clinic |
| Neurological | Arm abduction held for two minutes without fatigue; speech clear while counting to 50 |
| Skin | No suspicious lesions |
| Psychiatric | Calm, direct and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Drooping eyelids and double vision for six weeks, worse in the evening, with fatigable weakness of the arms and neck, tiring when chewing and a nasal voice after long talks; a disorder of the neuromuscular junction suspected | resolved | confirmed | H53.2 | S — Synthetic presenting problem, resolved at the second visit when antibodies and nerve testing established myasthenia gravis. |
| Generalized myasthenia gravis, acetylcholine receptor antibody positive, MGFA class IIa, without thymoma; synthetic modern detail linked to her documented myasthenia gravis of 1980 | active | confirmed | G70.00 | S — Synthetic antibody level, electrodiagnosis, class and treatment; the diagnosis less than a year after the crash, and recovery with Cherokee medicine people, surgery and drug therapy, are documented (D). |
| Autosomal dominant polycystic kidney disease (hereditary, as she has described it), with normal kidney function; to be staged | active | confirmed | Q61.2 | S — The hereditary polycystic kidney disease is documented (D) from her later public account; its detection before the index date, and every value, are synthetic. |
| Recovery from major trauma in a head-on car crash last year: fractures of both legs, ribs and face, with many operations; walks independently, with a cane on rough ground | active | confirmed | Z87.81 | S — The crash, the operations and the injuries are documented (D); the current function is synthetic. |
| Long-term glucocorticoid therapy for myasthenia gravis, with monitoring of glucose, blood pressure, weight, bone health, mood, sleep, eyes and infection | active | confirmed | Z79.52 | S — Synthetic treatment plan. |
| Azathioprine as steroid-sparing therapy, with blood count and liver test monitoring | active | confirmed | Z79.624 | S — Synthetic treatment plan. |
| Acquired absence of the thymus after robotic extended thymectomy for myasthenia gravis (pathology: thymic follicular hyperplasia, no thymoma) | active | confirmed | Z90.89 | S — Synthetic: recorded after the thymectomy; the sources name surgery among her treatments without saying which. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 120/76 mm Hg |
| Depression screening | Completed today | PHQ-9 score 3 |
| Unhealthy alcohol use screening | Completed today | AUDIT-C score 0 |
| Tobacco use | Completed today | Never |
| Intimate partner violence screening | Completed today | Negative; she feels safe at home |
| Cervical cancer screening | Up to date | HPV test two years ago, negative; on long-term immunosuppression the interval will be reviewed with her at the next visit |
| Breast cancer screening | Not indicated | Mammography every two years begins at 40 |
| HIV screening | Ordered | Once for adults 15 to 65; no record of a test; drawn today |
| Hepatitis C screening | Ordered | Once for adults 18 to 79; drawn today with the HIV test |
| Hepatitis B | Up to date | Screened before azathioprine at the second visit: surface antigen and core antibody negative, surface antibody positive from childhood vaccination |
| Pneumococcal vaccine | Up to date | PCV20 at the second visit, before immunosuppression; no further doses needed |
| Recombinant zoster vaccine | Completed today | Dose 2 given today; series complete |
| Influenza vaccine | Due | Inactivated vaccine when this season's supply arrives; no live vaccines on azathioprine |
| COVID-19 vaccine | Due | This season's vaccine in the autumn; she is on immunosuppression |
| Tetanus, diphtheria and pertussis | Up to date | Tdap given in hospital after the crash last year |
| Measles, mumps, rubella and varicella vaccines | Not indicated | Live vaccines are not given on azathioprine and prednisone; immunity to be checked if exposure occurs |
| HPV vaccine | Not indicated | Over 26; shared decision offered for 27 to 45 and not wanted |
| Folic acid | Not indicated | Not planning pregnancy; 0.4 to 0.8 mg daily advised before any planned pregnancy, which should also be planned with neuromuscular neurology because of her medicines |
| Cholesterol screening | Not indicated | Statin screening begins at 40; no diabetes or other indication |
| Bone health on glucocorticoids | Up to date | DXA at the third visit: Z-scores normal; calcium and vitamin D daily |
| Skin cancer prevention | Completed today | Counseled on hat and sunscreen; yearly skin check on azathioprine |
Immunizations given today: Recombinant zoster vaccine, dose 2 of 2 [S]
Guideline basis: Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Adult Immunization Schedule by Medical Condition and Other Indication (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026)
Follow-up: Seven-month review in seven weeks with neuromuscular neurology input, blood count, liver and kidney tests, hemoglobin A1c and urine albumin. Influenza and COVID-19 vaccines then. Next preventive visit in one year. Next scheduled visit 2026-10-12: seven-month review: minimal manifestation status, prednisone and pyridostigmine reduction, azathioprine safety, kidney screening, and plans for the year. [S]
Voluntary advance care planning discussion of about 20 minutes, with her consent. She named a health care agent, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. She said that what matters most to her is to keep working for her community, to be told plainly what is happening, and to make her own decisions, with her own Cherokee medicine respected. She chose not to record specific treatment preferences today, and knows that the plan can be updated at any visit. [S]